Dr. Jemsek’s innovations in the treatment of Lyme disease (Lyme borreliosis complex)

Lyme borreliosis: Changing the landscape

For twenty-five years, Dr. Jemsek pushed the boundaries of medicine in search of answers for his patients suffering from Lyme disease. Along the way, he challenged his own knowledge of medicine, clashed with colleagues and academics, grappled with policymakers, and faced up to a stream of slander and legal battles. Despite it all, Dr. Jemsek continued his fight for the privilege of serving his patients — who, in turn, rewarded him with their gratitude every day.

Key Innovations

2004

Dr. Jemsek coined the term Lyme borreliosis complex (LBC) as a moniker for persistent Lyme disease, defining it as a polymicrobial infection (with multiple co-pathogens) with multisystem involvement, multicompartmental neurologic manifestations, and immune evasion and immune suppression mechanisms.

2005

Dr. Jemsek recognized T and B immune cell depletion and identified LBC as a co-factor in the expression of multiple chronic illnesses of unknown cause and presented his hypothesis at multiple conferences.

2006

Dr. Jemsek recognized subacute acalculous cholecystitis as a common syndrome affecting patients of all ages with LBC, a diagnostic syndrome not yet in surgical texts.

2007

Dr. Jemsek developed the concept of a maintenance phase for patients having completed core treatment, in order to lock in immunologic gains.

2011

Influenced by the research and clinical practice of Dr. Robert Bransfield, Dr. Jemsek first emphasized the neuro-anatomical manifestations of LBC and presented on them at ILADS and other conferences. He also introduced the use of IV lactated ringers solution as a major detoxification tool, particularly in patients undergoing an IV-based program.

2012

He began employing sugar alcohols targeting biofilm colonies, with overwhelming clinical evidence that babesia sequesters itself in biofilm throughout the body.

2014

Dr. Jemsek introduced the management of non-hepatic hyperammonemia, with emphasis on reviewing genetic methylation pathways.

2015

He crafted a kefir cocktail recipe to promote gut health, especially in histamine-tolerant patients!

2016

Dr. Jemsek recognized that, late in treatment, approximately 30% of patients with LBC show an immune reconstitution syndrome with migratory arthralgias, dermal flushing, and intensification of neuropsychiatric symptomatology, analogous to the immune reconstitution inflammatory syndrome seen in patients with HIV/AIDS.

He also identified C2/V1 as the origin of the classic cervicofacial headache, often confused with migraine headache.

2018

Dr. Jemsek recognized and defined involuntary weight gain in patients with LBC, indicative of a continued inflammatory state.

2019

Co-authored the design, in collaboration with the Global Lyme Alliance (GLA), of the first clinical study aimed at determining the effectiveness of physician-developed Lyme treatment regimens; a number of patients would be followed over time to monitor a range of microbiological, immunological, genetic, and metabolic assays, to assess clinical improvement.